<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ergonovine (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ergonovine (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ergonovine (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11642" href="/d/html/11642.html" rel="external">see "Ergonovine (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F166263"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ergot Derivative;</li>
<li>
                        Oxytocic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F166247"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b2a7edc-7259-40ae-8809-5acc51f83f50">Treatment/prevention of postpartum or postabortion hemorrhage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Treatment/prevention of postpartum or postabortion hemorrhage:</b>
<b>IM, IV</b> (IV should be reserved for emergency use only): 0.2 mg, may repeat dose every 2 to 4 hours if needed, up to maximum of 5 total doses. A 0.25 mg dose may also be used for the treatment of postpartum hemorrhage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36567097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36567097'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="998b0e48-f78b-477e-9e99-895012748337">Intracoronary provocation testing for vasospastic angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracoronary provocation testing for vasospastic angina (off-label use):</b>
<b>Intracoronary (off-label route):</b> 20 to 60 mcg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23996286','lexi-content-ref-25273915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23996286','lexi-content-ref-25273915'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block adr drugH1Div" id="F166222"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, chest pain, palpitations, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Water intoxication</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, nausea, unpleasant taste, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, hallucination, headache, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, nasal congestion</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Tsui 2001), collapse (Valentine 1977), complete atrioventricular block (Wang 2017), coronary artery vasospasm (Bamrah 1984), increased serum creatine kinase, sick sinus syndrome (Wang 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye movement disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (Crawford 1980)</p></div>
<div class="block coi drugH1Div" id="F166234"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ergonovine, other ergot preparations, or any component of the formulation; induction of labor, threatened spontaneous abortion, toxemia; hypertension; breastfeeding (if &gt;1 dose is administered); concomitant use of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors (Note: the product labeling for other potent CYP3A4 inhibitors [eg, azole antifungals, some macrolide antibiotics] contraindicates concomitant use with ergot derivatives.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F166219"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ergotism: Prolonged therapy may lead to gangrene and other signs of ergotism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease; coronary vasoconstriction may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Uterine response may be insufficient in calcium deficient patients. Responsiveness may be restored with cautious use of IV calcium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: Use with extreme caution when administering IV; risk of inducing sudden hypertensive and cerebrovascular accidents.</p>
<p style="text-indent:-2em;margin-left:4em;">• General anesthesia: May cause nausea/vomiting; use caution when administered to patients undergoing general anesthesia.</p></div>
<div class="block prod-avail drugH1Div" id="F13690182"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040723"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52866770"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg/mL (1 mL)</p></div>
<div class="block adm drugH1Div" id="F166231"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV or IM:</b> May be administered by IV or IM injection. IV use should be limited to patients with severe uterine bleeding or other life-threatening emergency situations. IV doses should be administered over a period of ≥1 minute.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracoronary (off-label use/route):</b> For provocation testing during coronary angiography, mix in normal saline and inject slowly over 2 to 5 minutes into left coronary artery; perform coronary angiography 1 to 2 minutes after completion of injection. If negative result, proceed with right coronary artery provocation in a similar fashion over 2 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25273915']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25273915'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132443"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F166230"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postpartum or postabortion hemorrhage:</b> Prevention and treatment of postpartum and postabortion hemorrhage caused by uterine atony</p></div>
<div class="block off-label drugH1Div" id="F25725537"><span class="drugH1">Use: Off-Label: Adult</span><p>Vasospastic angina (diagnostic identification)</p></div>
<div class="block mst drugH1Div" id="F46782802"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">ALERT: Canadian Boxed Warning: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F166257"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F166224"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may enhance the vasoconstricting effect of Alpha1-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: Ergot Derivatives may enhance the adverse/toxic effect of Bromocriptine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dihydroergotamine: Ergot Derivatives may enhance the vasoconstricting effect of Dihydroergotamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the adverse/toxic effect of Ergot Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin (Withdrawn From US Market) may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: Ergot Derivatives may enhance the vasoconstricting effect of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may diminish the vasodilatory effect of Nitroglycerin. Nitroglycerin may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).  Management: Avoid the use of ergot derivatives in patients receiving nitroglycerin for angina (or in any angina patient) if possible. If combined, monitor for decreased effects of nitroglycerin and increased adverse effects of the ergot derivative (eg, ergotism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the adverse/toxic effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: May enhance the hypertensive effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the serum concentration of Ergonovine. Specifically, this would be most likely with delavrdine, while other Non-Nucleoside Reverse Transcriptase Inhibitors may be more likely to decrease the concentration of Ergonovine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxithromycin: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Ergot Derivatives may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F166236"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Ergonovine is used in the third stage of labor for the prevention or treatment of postpartum hemorrhage and should not be used prior to delivery of the placenta. Prior to administration, the placenta should be delivered and the possibility of twin pregnancy ruled out. Ergonovine is not the preferred agent for the prevention of postpartum hemorrhage due to an increased risk of adverse maternal events (SOGC [Robinson 2022]). Rule out hypertensive disorders prior to use (FIGO [Escobar 2022]).</p></div>
<div class="block brc drugH1Div" id="F13690180"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Ergonovine may suppress prolactin secretion leading to decreased breastfeeding rates (Jordan 2009). May cause ergotism in breastfeeding infants. According to the manufacturer, breastfeeding is contraindicated when more than a single dose of ergonovine is administered to the postpartum mother. Administration of a single dose of ergonovine does not preclude a mother from nursing.</p></div>
<div class="block mop drugH1Div" id="F2984497"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Postpartum hemorrhage: Heart rate, BP, blood loss, temperature (FIGO [Escobar 2022]).</p></div>
<div class="block pha drugH1Div" id="F166218"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Similar smooth muscle actions as seen with ergotamine; however, it affects primarily uterine smooth muscles producing sustained contractions and thereby shortens the third stage of labor. Has slight alpha-adrenergic blocking activity and produces less vasoconstriction than ergotamine.</p></div>
<div class="block phk drugH1Div" id="F166233"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: IM: 2 to 5 minutes; IV: Immediate </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: IM: Uterine effect: ≥3 hours; IV: ~45 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539854"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ergotrate</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ergometrin | Ergometrine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ergometrin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ergometrin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ergotrate</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">DBL Ergometrine Maleate</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ergometrine maleat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ergometrin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ergometrin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6470347">
<a name="6470347"></a>Bamrah VS, Schuchard GJ. Refractory coronary artery spasm. <i>J Am Coll Cardiol</i>. 1984;4(3):635-639. doi:10.1016/s0735-1097(84)80114-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/6470347/pubmed" id="6470347" target="_blank">6470347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7435910">
<a name="7435910"></a>Crawford JS. Bronchospasm following ergometrine. <i>Anaesthesia</i>. 1980;35(4):397-398. doi:10.1111/j.1365-2044.1980.tb05138.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/7435910/pubmed" id="7435910" target="_blank">7435910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9806101">
<a name="9806101"></a>de Groot AN, van Dongen PW, Vree TB, et al, “Ergot Alkaloids. Current Status and Review of Clinical Pharmacology and Therapeutic Use Compared With Other Oxytocics in Obstetrics and Gynaecology,” <i>Drugs</i>, 1998, 56(4):523-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/9806101/pubmed" id="9806101" target="_blank">9806101</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ergonovine maleate injection [product monograph]. Mississauga, Ontario, Canada: Teligent Canada Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35297039">
<a name="35297039"></a>Escobar MF, Nassar AH, Theron G, et al; FIGO Safe Motherhood and Newborn Health Committee. FIGO recommendations on the management of postpartum hemorrhage 2022. <i>Int J Gynaecol Obstet</i>. 2022;157(suppl 1):3-50. doi:10.1002/ijgo.14116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/35297039/pubmed" id="35297039" target="_blank">35297039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fuster.1">
<a name="Fuster.1"></a>Fuster V, Topol EJ, and Nabel EG, eds, <i>Atherothrombosis and Coronary Artery Disease</i>, 2nd ed, Philadelphia, PA: Lippincott Williams &amp; Wilkens, 2004.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25273915">
<a name="25273915"></a>JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina). <i>Circ J</i>. 2014;78(11):2779-2801. doi: 10.1253/circj.cj-66-0098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/25273915/pubmed" id="25273915" target="_blank">25273915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19735379">
<a name="19735379"></a>Jordan S, Emery S, Watkins A, et al. Associations of drugs routinely given in labour with breastfeeding at 48 hours: analysis of the Cardiff Births Survey. <i>BJOG</i>. 2009;116(12):1622-1629. doi:10.1111/j.1471-0528.2009.02256.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/19735379/pubmed" id="19735379" target="_blank">19735379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23996286">
<a name="23996286"></a>Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>Eur Heart J</i>. 2013;34(38):2949-3003. doi: 10.1093/eurheartj/eht296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/23996286/pubmed" id="23996286" target="_blank">23996286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2909157">
<a name="2909157"></a>Previtali M, Ardissino D, Barberis P, Panciroli C, Chimienti M, Salerno JA. Hyperventilation and ergonovine tests in Prinzmetal's variant angina pectoris in men. <i>Am J Cardiol</i>. 1989;63(1):17-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/2909157/pubmed" id="2909157" target="_blank">2909157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36567097">
<a name="36567097"></a>Robinson D, Basso M, Chan C, Duckitt K, Lett R. Guideline no. 431: postpartum hemorrhage and hemorrhagic shock. <i>J Obstet Gynaecol Can</i>. 2022;44(12):1293-1310.e1. doi:10.1016/j.jogc.2022.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/36567097/pubmed" id="36567097" target="_blank">36567097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10841234">
<a name="10841234"></a>Song JK, Park SW, Kang DH, Hong MK, Kim JJ, Lee CW, Park SJ. Safety and clinical impact of ergonovine stress echocardiography for diagnosis of coronary vasospasm. <i>J Am Coll Cardio</i>l. 2000;35(7):1850-1856.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/10841234/pubmed" id="10841234" target="_blank">10841234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8916990">
<a name="8916990"></a>Soriano D, Dulitzki M, Schiff E, et al, “A Prospective Cohort Study of Oxytoxin Plus Ergometrine Compared With Oxytocin Alone for Prevention of Postpartum Heamorrhage,” <i>Br J Obstet Gynaecol</i>, 1996, 103(11):1068-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/8916990/pubmed" id="8916990" target="_blank">8916990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12966266">
<a name="12966266"></a>Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, Uraoka T. Induction of coronary artery spasm by two pharmacological agents: comparison between intracoronary injection of acetylcholine and ergonovine. <i>Coron Artery Dis</i>. 2003;14(6):451-457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/12966266/pubmed" id="12966266" target="_blank">12966266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15585990">
<a name="15585990"></a>Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, Uraoka T. Clinical impact of selective spasm provocation tests: comparisons between acetylcholine and ergonovine in 1508 examinations. <i>Coron Artery Dis</i>. 2004;15(8):491-497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/15585990/pubmed" id="15585990" target="_blank">15585990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22782943">
<a name="22782943"></a>Takagi Y, Yasuda S, Takahashi J, et al; Japanese Coronary Spasm Association. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmic complications, and prognostic impact: multicentre registry study of the Japanese Coronary Spasm Association. <i>Eur Heart J</i>. 2013;34(4):258-267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/22782943/pubmed" id="22782943" target="_blank">22782943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11176106">
<a name="11176106"></a>Tsui BC, Stewart B, Fitzmaurice A, Williams R. Cardiac arrest and myocardial infarction induced by postpartum intravenous ergonovine administration. <i>Anesthesiology</i>. 2001;94(2):363-364. doi:10.1097/00000542-200102000-00033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/11176106/pubmed" id="11176106" target="_blank">11176106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-831748">
<a name="831748"></a>Valentine BH, Martin MA, Phillips NV. Collapse during operation following i.v. ergometrine. A case report. <i>Br J Anaesth</i>. 1977;49(1):81-82. doi:10.1093/bja/49.1.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/831748/pubmed" id="831748" target="_blank">831748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095320">
<a name="29095320"></a>Wang HT, Liu WH, Chen YL. Transient sick sinus syndrome with complete atrioventricular block associated with ergonovine intake: a case report. <i>Medicine (Baltimore)</i>. 2017;96(44):e8559. doi:10.1097/MD.0000000000008559<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/29095320/pubmed" id="29095320" target="_blank">29095320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9527075">
<a name="9527075"></a>Yamada T, Okamoto M, Sueda T, Hashimoto M, Matsuura H, Kajiyama G. Ergonovine-induced alterations in coronary flow velocity preceding onset of occlusive spasm in patients without significant coronary artery stenoses. <i>Am J Cardiol</i>. 1998;81(6):688-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergonovine-united-states-not-available-drug-information/abstract-text/9527075/pubmed" id="9527075" target="_blank">9527075</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9415 Version 191.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
